Related Experiment Video
Updated: Jul 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in
Mikihiko Kawano1, Shoichiro Nagasaka, Hiroaki Yagyu
1Department of Comprehensive Medicine, Jichi Medical University, Omiya Medical Center, Saitama-shi, Saitama-ken, Japan. mkkawano@jichi.ac.jp
Aim:
Prebeta1-HDL is involved in the initial step of cholesterol efflux from peripheral cells and plays an important role in reverse cholesterol transport. We studied the effect of pitavastatin on the HDL subfraction profile, prebeta1-HDL concentration and its disappearance rate.
Methods:
Twenty-nine hypercholesterolemic patients were treated with pitavastatin at 2 mg/day for 4 weeks, and plasma levels of total cholesterol (TC), triglyceride, HDL-cholesterol (C), HDL(2)-C, HDL(3)-C, prebeta1-HDL, LCAT activity, and CETP mass were assayed. The prebeta1-HDL disappearance rate was determined as the difference in prebeta1-HDL concentration before and after incubation at 37 degrees C for 90 min divided by the pre-incubation prebeta1-HDL concentration.
Results:
Pitavastatin led to significant decreases in TC by 26.9% and LDL-C by 39.8%. HDL-C and HDL(2)-C increased significantly by 6.0% and 9.0%, respectively, but there was no significant change in HDL(3)-C. Prebeta1-HDL concentration significantly decreased (-8.7%; p<0.05); however, its disappearance rate significantly increased (13.0%; p<0.05). There were significant decreases in both LCAT activity and CETP mass.
Conclusion:
Although pitavastatin decreased plasma prebeta1-HDL concentration, it increased the prebeta1-HDL disappearance rate. These data suggest that pitavastatin might promote the early step of reverse cholesterol transport.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Coronary Artery Disease IV: Preventive Measures
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...